This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

This study has been completed.
Information provided by (Responsible Party):
McMaster University Identifier:
First received: July 25, 2008
Last updated: February 7, 2012
Last verified: July 2009
The study was designed to examine the efficacy and tolerability of quetiapine XR for the treatment of women who suffer from depression in the context of the menopausal transition and postmenopausal years. Besides the improvement of depressive symptoms, the investigators are interested in examining the impact of this medication on vasomotor symptoms (hot flashes, night sweats), sleep and overall quality of life.

Condition Intervention Phase
Major Depressive Disorder Insomnia Hot Flashes Drug: Quetiapine Extended Release Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Seroquel XR for the Treatment of Peri and Postmenopausal Women With Major Depressive Disorder: Impact on Mood, Physical Symptoms, Sleep and Quality of Life

Resource links provided by NLM:

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Changes in depressive scores (MADRS) from baseline (after a 2-week lead-in phase) to study end [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Changes in Menopause-related scores, based on the Greene Climacteric Scale (GCS) and Hot Flash Related daily interference Scale (HFRDIS) [ Time Frame: 8 weeks ]

Enrollment: 40
Study Start Date: June 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
Drug: Quetiapine Extended Release
Quetiapine XR, 150-300 mg QHS, for 8 weeks
Other Name: Quetiapine extended-release (Seroquel XR)

Detailed Description:

The menopause transition (or perimenopause) and the early postmenopausal years are marked by intense hormone fluctuations; hormone changes are frequently accompanied by the occurrence hot flashes, night sweats and sleep disturbance. Recent epidemiologic studies also demonstrate that perimenopause is a period of greater risk for the development of depressive symptoms.

To date, serotonergic antidepressants such as paroxetine and escitalopram have shown to be efficacious for the treatment of women with depression and menopause-related symptoms. We hypothesize that the use of quetiapine for this sub-population will alleviate symptoms of depression; we also anticipate that its use may enhance quality of life and improve vasomotor symptoms - the latter possibly due to quetiapine's effect on 5HT receptors and/or due to its sleep-promoting properties (e.g., by increasing the duration of total sleep time [TST], enhancing sleep efficiency, and decreasing the number of awakenings due to hot flashes).


Ages Eligible for Study:   40 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women 40 to 60 years
  • diagnosis of MDD
  • perimenopausal or postmenopausal

Exclusion Criteria:

  • using HRT
  • using psychotropic medications
  • other DSM-IV axis I diagnoses other than MDD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00723970

Canada, Ontario
Women's Health Concerns Clinic (WHCC)
Hamilton, Ontario, Canada, L8P 3B6
Sponsors and Collaborators
McMaster University
Principal Investigator: Claudio N Soares, MD, PhD St. Joseph's Healthcare Hamilton, McMaster University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: McMaster University Identifier: NCT00723970     History of Changes
Other Study ID Numbers: D1443C00008
Study First Received: July 25, 2008
Last Updated: February 7, 2012

Keywords provided by McMaster University:
Major Depressive Disorder
Hot Flashes

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Sleep Initiation and Maintenance Disorders
Hot Flashes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Signs and Symptoms
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on August 18, 2017